Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 11/20 | 0.65 |
| ▸ | ORAI1 | Q96D31 | 11/20 | 0.65 |
| ▸ | LDHA | P00338 | 2/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.57 |
| ▸ | ESRRA | P11474 | 3/20 | 0.57 |
| ▸ | TRPC1 | P48995 | 3/20 | 0.56 |
| ▸ | TRPC3 | Q13507 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.54 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.52 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.52 |
| ▸ | STIM2 | Q9P246 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2709787 | 0.89 | STIM1 (0.62) | STIM1ORAI1LDHAKEAP1NFE2L2 | |
| SCHEMBL26803794 | 0.86 | STIM1 (0.69) | STIM1ORAI1LDHAKEAP1NFE2L2 | |
| SCHEMBL26915272 | 0.86 | P2RY14 (0.57) | STIM1ORAI1ESRRAP2RY14 | |
| SCHEMBL182264 | 0.86 | P2RY14 (0.57) | STIM1ORAI1ESRRAP2RY14 | |
| SCHEMBL29946192 | 0.86 | STIM1 (0.76) | STIM1ORAI1LDHAKEAP1NFE2L2 | |
| SCHEMBL26628304 | 0.86 | STIM1 (0.76) | STIM1ORAI1LDHAKEAP1NFE2L2 | |
| SCHEMBL29946232 | 0.84 | STIM1 (0.66) | STIM1ORAI1LDHAKEAP1NFE2L2 | |
| SCHEMBL26628324 | 0.84 | STIM1 (0.66) | STIM1ORAI1LDHAKEAP1NFE2L2 | |
| SCHEMBL21122080 | 0.83 | STIM1 (0.65) | STIM1ORAI1LDHAKEAP1NFE2L2 | |
| SCHEMBL1429965 | 0.83 | STIM1 (0.83) | STIM1ORAI1LDHAKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096165-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2013-04-18 | — | — | US | claimed |
| US-20110172278-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2011-07-14 | — | — | US | claimed |
| CN-102076670-A | Compounds and methods for modulating g protein-coupled receptors | IRM LLC | 2011-05-25 | — | — | CN | claimed |
| EP-2300442-A2 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2011-03-30 | — | — | EP | claimed |
| WO-2010008831-A2 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2010-01-21 | — | — | WO | claimed |
| CN-102076670-B | Compounds and methods for modulating g protein-coupled receptors | IRM LLC | 2013-05-22 | — | — | CN | disclosed |
| US-20130096165-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2013-04-18 | — | — | US | disclosed |
| US-20130096165-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2013-04-18 | — | — | US | disclosed |
| US-8362050-B2 | Compounds and methods for modulating G protein-coupled receptors | IRM LLC (BM) | 2013-01-29 | — | — | US | disclosed |
| US-8362050-B2 | Compounds and methods for modulating G protein-coupled receptors | IRM LLC (BM) | 2013-01-29 | — | — | US | disclosed |
| US-20110172278-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2011-07-14 | — | — | US | disclosed |
| US-20110172278-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2011-07-14 | — | — | US | disclosed |
| CN-102076670-A | Compounds and methods for modulating g protein-coupled receptors | IRM LLC | 2011-05-25 | — | — | CN | disclosed |
| EP-2300442-A2 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010008831-A2 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010008831-A2 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | IRM LLC (BM) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096165-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | GRK2, GRK3, GPR3 | STIM1 1019/4885ORAI1 1521/4885LDHA 4710/4885 |
| US-20110172278-A1 | COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS | GRK2, GRK3, GPR3 | STIM1 1019/4885ORAI1 1521/4885LDHA 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.